Literature DB >> 22733126

Genome-wide supported variant MIR137 and severe negative symptoms predict membership of an impaired cognitive subtype of schizophrenia.

M J Green1, M J Cairns, J Wu, M Dragovic, A Jablensky, P A Tooney, R J Scott, V J Carr.   

Abstract

Progress in determining the aetiology of schizophrenia (Sz) has arguably been limited by a poorly defined phenotype. We sought to delineate empirically derived cognitive subtypes of Sz to investigate the association of a genetic variant identified in a recent genome-wide association study with specific phenotypic characteristics of Sz. We applied Grade of Membership (GoM) analyses to 617 patients meeting ICD-10 criteria for Sz (n=526) or schizoaffective disorder (n=91), using cognitive performance indicators collected within the Australian Schizophrenia Research Bank. Cognitive variables included subscales from the Repeatable Battery for the Assessment of Neuropsychological Status, the Controlled Oral Word Association Test and the Letter Number Sequencing Test, and standardised estimates of premorbid and current intelligence quotient. The most parsimonious GoM solution yielded two subtypes of clinical cases reflecting those with cognitive deficits (CDs; N=294), comprising 47.6% of the sample who were impaired across all cognitive measures, and a cognitively spared group (CS; N=323) made up of the remaining 52.4% who performed relatively well on all cognitive tests. The CD subgroup were more likely to be unemployed, had an earlier illness onset, and greater severity of functional disability and negative symptoms than the CS group. Risk alleles on the MIR137 single-nucleotide polymorphism (SNP) predicted membership of CD subtype only in combination with higher severity of negative symptoms. These findings provide the first evidence for association of the MIR137 SNP with a specific Sz phenotype characterised by severe CDs and negative symptoms, consistent with the emerging role of microRNAs in the regulation of proteins responsible for neural development and function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22733126     DOI: 10.1038/mp.2012.84

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  64 in total

Review 1.  MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.

Authors:  Andrea de Bartolomeis; Felice Iasevoli; Carmine Tomasetti; Elisabetta F Buonaguro
Journal:  Mol Neurobiol       Date:  2014-11-14       Impact factor: 5.590

Review 2.  Heterogeneity and individuality: microRNAs in mental disorders.

Authors:  Leif G Hommers; Katharina Domschke; Jürgen Deckert
Journal:  J Neural Transm (Vienna)       Date:  2014-11-14       Impact factor: 3.575

3.  Genes and schizophrenia: from a Festschrift Seminar honoring William T. Carpenter Jr, MD.

Authors:  Anil K Malhotra
Journal:  Schizophr Bull       Date:  2013-10-10       Impact factor: 9.306

4.  The schizophrenia risk gene MIR137 acts as a hippocampal gene network node orchestrating the expression of genes relevant to nervous system development and function.

Authors:  Nikkie F M Olde Loohuis; Nael Nadif Kasri; Jeffrey C Glennon; Hans van Bokhoven; Sébastien S Hébert; Barry B Kaplan; Gerard J M Martens; Armaz Aschrafi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2016-02-27       Impact factor: 5.067

5.  MicroRNA-137 regulates a glucocorticoid receptor-dependent signalling network: implications for the etiology of schizophrenia.

Authors:  Astrid Vallès; Gerard J M Martens; Peter De Weerd; Geert Poelmans; Armaz Aschrafi
Journal:  J Psychiatry Neurosci       Date:  2014-09       Impact factor: 6.186

Review 6.  Dysregulation of miRNA and its potential therapeutic application in schizophrenia.

Authors:  Ting Cao; Xue-Chu Zhen
Journal:  CNS Neurosci Ther       Date:  2018-03-12       Impact factor: 5.243

7.  Reciprocal Alterations in Regulator of G Protein Signaling 4 and microRNA16 in Schizophrenia.

Authors:  Sohei Kimoto; Jill R Glausier; Kenneth N Fish; David W Volk; H Holly Bazmi; Dominique Arion; Dibyadeep Datta; David A Lewis
Journal:  Schizophr Bull       Date:  2015-09-30       Impact factor: 9.306

8.  Differential regulation of schizophrenia-associated microRNA gene function by variable number tandem repeats (VNTR) polymorphism.

Authors:  Mohammed Mamdani; Gowon O McMichael; Venkat Gadepalli; Vernell Williamson; Erin K Parker; Vahram Haroutunian; Vladimir I Vladimirov
Journal:  Schizophr Res       Date:  2013-11-07       Impact factor: 4.939

Review 9.  The epigenome and postnatal environmental influences in psychotic disorders.

Authors:  Ehsan Pishva; Gunter Kenis; Daniel van den Hove; Klaus-Peter Lesch; Marco P M Boks; Jim van Os; Bart P F Rutten
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-02-19       Impact factor: 4.328

Review 10.  An emerging role for microRNAs in sexually dimorphic neurobiological systems.

Authors:  Toni R Pak; Yathindar S Rao; Sarah A Prins; Natasha N Mott
Journal:  Pflugers Arch       Date:  2013-02-09       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.